Nano-X Imaging

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Neve Ilan, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nano-X Imaging reports progress in regulatory clearances and strategic partnerships

Nano-X Imaging showcased progress in regulatory clearances, commercialization efforts, strategic partnerships, and operational optimization during the Q4 2022 Earnings Call.
Despite challenges in regulatory compliance, expenses management, and market competition, the company's strengths in innovation, partnerships, and financial resilience position it well for future growth.
Opportunities for Nano-X Imaging include global expansion, technological advancements, cost efficiencies, and leveraging market demand for imaging solutions.
Overall, Nano-X Imaging's performance in Q4 2022 reflects a strategic focus on growth, innovation, and market expansion in the medical imaging industry.

Nano-X Imaging reports improved Q1 performance and expands global reach

Nano-X Imaging's Q1 2023 performance showed improvement with a reported net loss of $11.8 million and revenue of $2.4 million. The company is focusing on deploying Nanox.ARC globally, strengthening manufacturing capabilities, and expanding market reach through strategic partnerships. Challenges include managing expenses and driving revenue growth to achieve profitability.

Nanox Imaging reports Q2 results, eyes U.S. market growth

Nanox Imaging's Q2 2023 performance reflects investment in growth initiatives, with a focus on market expansion and product deployment.
The company faces financial challenges, including a significant net loss and accrued expenses related to an SEC investigation, necessitating prudent financial management.
Strategic strengths in the U.S. market entry, global commercialization efforts, and strong cash position position Nanox Imaging for future growth and market success.
Opportunities lie in upcoming Investor Day, FDA clearance for Nanox.ARC, and expansion in Africa, offering avenues for revenue growth and market leadership.

Nanox Imaging reports Q3 revenue growth and strategic advancements

Nanox Imaging's Q3 2023 performance showed revenue growth and strategic advancements. While facing financial challenges and potential execution hurdles, the company's focus on expansion and partnerships positions it for future growth.

Nanox Imaging reports Q4 loss, eyes global expansion and AI

Nanox Imaging's Q4 2023 performance showed a mix of revenue growth and strategic investments in technology and market expansion.
The company's strengths lie in its progress with regulatory clearances, commercialization efforts, and success in AI applications.
Challenges include slow AI adoption, implementation hurdles, and the need to overcome barriers to data sharing and transparency.
Opportunities exist in expanding HealthCCS usage, global market presence, and addressing AI adoption challenges for revenue growth.

Nanox Imaging reports Q1 loss, eyes global expansion and AI growth

Nanox Imaging's Q1 2024 performance reflects revenue generation from AI solutions and system sales amid challenges in gross profit margins and a notable net loss.
The company's strategic strengths in partnerships, product launches, and global expansions position it well for future growth and market competitiveness.
While facing challenges in cost management and profitability, Nanox Imaging holds opportunities in expanded indications, market expansions, and AI solutions deployment.

Nano-X Imaging reports Q2 losses, eyes growth through FDA clearances

Nano-X Imaging (NNOX) showcased progress in commercial and clinical fronts but faces challenges in narrowing losses and optimizing operations.
Strategic collaborations, FDA clearances, and global deployment offer opportunities for growth and market expansion.
The focus on transformative imaging solutions and commercial infrastructure acceleration underlines NNOX's commitment to innovation and market leadership.

Nanox Imaging reports mixed Q3 results amidst growth opportunities

Nanox Imaging reported mixed financial results with revenue of $3.0 million and a gross loss of $2.8 million, while achieving record revenue from USARAD business.
The company showcased strengths in technology deployment, partnerships, and clinical trials, but faces challenges in regulatory clearances and financial performance.
Opportunities exist in market expansion, revenue growth, and operational efficiency improvements to drive future success and profitability.
With a strong focus on innovation, partnerships, and market expansion, Nanox is poised for growth but needs to address regulatory hurdles and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Petach Tikva, Israel.

Amyris

Renalytix AI plc

These potential stock rockets are well worth the different risks they present.

3 High-Growth Healthcare Stocks to Buy in August

Align Technology

Guardant Health Inc

Pfizer

There's both rhyme and reason for checking out these four stocks.

Missed Out on the FAANG Stocks? Consider Buying These PfANG Stocks Instead.

Management to host conference call and webcast at 8:30 AM ET on that day Management to host conference call and webcast at 8:30 AM ET on that day

Nanox to Announce Second Quarter 2021 Financial and Operating Results on Tuesday, August 10, 2021

Beam Therapeutics

DermTech Inc

They're disruptors that could change healthcare.

3 Healthcare Stocks That Could Make You Rich

NANO-X Imaging Ltd (NASDAQ: NNOX) signs an exclusive distribution deal with EiLEENO Pharma to deploy Nanox's medical imaging services in Nigeria, marking its entry in West Africa. The Nanox System is composed of the Nanox.ARC, a medical imaging system incorporating a digital X-ray source, and the Nanox.CLOUD, a companion cloud-based software.

NANO-X, EiLEENO Pharma Ink Distribution Deal For Imaging Solutions In Nigeria

NEVE ILAN, Israel & KADUNA, Nigeria--(BUSINESS WIRE)-- #EiLEENO--Nanox Signs MSaaS Agreement for the Deployment of 1,000 Nanox Systems in Nigeria.

Nanox Signs MSaaS Agreement for the Deployment of 1,000 Nanox Systems in Nigeria

OptimizeRx Corp

OptimizeRx and Nano-X Imaging are two of my favorite small-caps right now. Here's why.

2 Top Small-Cap Stocks to Buy in July

The company's breakthrough multisource X-ray imaging device has investors excited.

Why Is Everyone Talking About Nano-X Stock?

NEVE ILAN, Israel, July 01, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announces that Nanox's Chairman and Chief Executive Officer Ran Poliakine will deliver a company presentation and the leadership team will host investor 1x1 meetings during the Ladenburg Thalmann Healthcare Conference, which is being held July 13th through July 14th.

Nanox to Present at the Ladenburg Thalmann Healthcare Conference

Nano-X just took a big step toward generating revenue.

Why Nano-X Imaging Stock Just Jumped 15%

Nano-X Imaging Ltd (NASDAQ:NNOX) shares climbed higher Thursday after the company announced it submitted a 510(k) premarket notification application to the U.S. Food and Drug Administration for the first version of its multi-source Nanox.ARC 3-D digital tomosynthesis system. Nano-X Imaging was up 11.47% at $31.19 at last check Thursday.

Here's Why Buyers Came Into Nano-X Imaging Thursday

The stock price of NANOX IMAGING LTD (NASDAQ: NNOX) increased by over 10% pre-market. This is why it happened.

NNOX Stock Price Increases Over 10% Pre-Market: Why It Happened

510(K) Class II FDA submission seeks clearance of the first version of company's multi-source 3-D digital tomosynthesis system as the next step in its U.S. regulatory process 510(K) Class II FDA submission seeks clearance of the first version of company's multi-source 3-D digital tomosynthesis system as the next step in its U.S. regulatory process

Nanox Announces FDA 510(k) Submission for First Version of Multi-Source Nanox.ARC

Nano-X is not a safe investment -- it's a highly risky one. But its potential upside is incredible.

Could Nano-X Be a Millionaire-Maker Stock?

NEVE ILAN, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announces that Nanox's Chairman and Chief Executive Officer Ran Poliakine will make a company presentation and the leadership team will host investor 1x1 meetings during the Jefferies Virtual Healthcare Conference, which is being held June 1st through June 4th.

Update – Nanox to Participate in the Jefferies Virtual Healthcare Conference

Nano-X Imaging (NASDAQ: NNOX) reported a first-quarter net loss of $12.7 million wider than $7.4 million reported a year ago. It clocked an adjusted net loss of $7.1 million, or EPS loss of ($0.15) better than the consensus of ($0.25) loss.

Why Are Nano-X Imaging (NNOX) Shares Plunging Today?

Nano-X Imaging Ltd (NNOX) CEO Rand Poliakine on Q1 2021 Results - Earnings Call Transcript

An earnings miss may be the least of this company's problems.

Why Nano-X Imaging Stock Just Crashed 14.5%

The small medical imaging technology company has hit a big snag.

The Surprise in Nano-X's Q1 Update That Caused the Stock to Crash

Announced FDA 510(k) clearance for the single source Nanox Cart X-Ray System

Nanox Announces First Quarter 2021 Results and Provides Business Update

Appointment adds to the Nanox team extensive experience in global medical business development and sales Appointment adds to the Nanox team extensive experience in global medical business development and sales

Nanox Announces Appointment of Medical Executive Moshe Shtengel as Chief Business Officer

AquaBounty Technologies

USHG Acquisition - Unit

If you've built a diversified portfolio, you can afford to take a small stake in these exciting companies.

3 High-Risk, High-Reward Stocks to Add to Your Watch List

With one regulatory hurdle cleared and one to go, the company is closer to success than ever before.

3 Green Flags for Nano-X That Could Make Investors Rich

Pinterest

PayPal

If data is the new oil, then these three businesses are tycoons in the making.

3 Companies Quietly Amassing Treasure Troves of Data

The stock price of Nano-X Imaging Ltd (NASDAQ: NNOX) increased by over 5% pre-market. This is why it happened.

News for Nano-X Imaging Stock (NNOX)